Abstract
Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor cells has been implicated in triggering a complex signal cascade that leads to increased tumor proliferation and survival. Cetuximab is a human-murine chimeric monoclonal antibody designed to target EGFR and competitively inhibit dimerization by circulating ligands. By this mechanism, it works to prevent this signal cascade thus hindering tumor proliferation. Cetuximab has been shown in a randomized phase III clinical trial to significantly increase overall survival when it is added to radiation therapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. In this manuscript, the mechanism of cetuximab with its associated patents is reviewed, with its role with chemotherapy and radiation in the management of head and neck cancer along with future directions of this targeted cancer therapy.
Keywords: Cetuximab, squamous cell carcinoma of the head and neck, radiation therapy, concurrent chemotherapy and radiation, epidermal growth factor receptor, targeted therapy
Recent Patents on Anti-Cancer Drug Discovery
Title: Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Volume: 3 Issue: 2
Author(s): Timothy D. Wagner and Gary Y. Yang
Affiliation:
Keywords: Cetuximab, squamous cell carcinoma of the head and neck, radiation therapy, concurrent chemotherapy and radiation, epidermal growth factor receptor, targeted therapy
Abstract: Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor cells has been implicated in triggering a complex signal cascade that leads to increased tumor proliferation and survival. Cetuximab is a human-murine chimeric monoclonal antibody designed to target EGFR and competitively inhibit dimerization by circulating ligands. By this mechanism, it works to prevent this signal cascade thus hindering tumor proliferation. Cetuximab has been shown in a randomized phase III clinical trial to significantly increase overall survival when it is added to radiation therapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. In this manuscript, the mechanism of cetuximab with its associated patents is reviewed, with its role with chemotherapy and radiation in the management of head and neck cancer along with future directions of this targeted cancer therapy.
Export Options
About this article
Cite this article as:
Wagner D. Timothy and Yang Y. Gary, Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638776
DOI https://dx.doi.org/10.2174/157489208784638776 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Impact of Viscosity and Refractive Index on Droplet Size and Zeta Potential of Model O/W and W/O Nanoemulsion
Current Nanoscience The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics
Current Pharmacogenomics Boron Containing Macromolecules and Nanovehicles as Delivery Agents for Neutron Capture Therapy†
Anti-Cancer Agents in Medicinal Chemistry Mind-Body Therapies and Osteoarthritis of the Knee
Current Rheumatology Reviews Peptide Self-Assembly for Therapeutic Applications
Current Organic Chemistry HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Dual Antibacterial and Anticancer Activity of 4-Benzoyl-1-dichlorobenzoylthiosemicarbazide Derivatives
Anti-Cancer Agents in Medicinal Chemistry Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Current Pharmaceutical Design Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Retraction Notice: Current Management of Vomiting After Tonsillectomy in Children
Current Drug Safety Targeting the Epidermal Growth Factor Receptor: Exploring the Potential of Novel Inhibitor N-(3-Ethynylphenyl)-6, 7-bis (2-methoxyethoxy) Quinolin- 4-Amine Using Docking and Molecular Dynamics Simulation
Protein & Peptide Letters Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) One Hundred Faces of Cyclopamine
Current Pharmaceutical Design An Unbiased Predictive Model to Detect DNA Methylation Propensity of CpG Islands in the Human Genome
Current Bioinformatics